US11629121B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11629121-B2 |
| Application number | US-201816620847-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 27, 2018 |
| Priority date | Jul 27, 2017 |
| Publication date | Apr 18, 2023 |
| Grant date | Apr 18, 2023 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The present invention relates to novel benzylideneacetone derivatives or uses thereof, more specifically, the present invention relates to a pharmaceutical composition for preventing or treating, or food composition for ameliorating a cancer or a bone disease comprising a compound defined by Formula 1 or pharmaceutically acceptable salt thereof as an active ingredient.
Opening claim text (preview).
The invention claimed is: 1. A method for treating a bone cancer in a subject, the method comprising administering to the subject in need thereof an effective amount of a composition comprising a compound defined by Formula 1 below or the pharmaceutically acceptable salt thereof as an active ingredient: wherein, R1 and R2 are different from each other, R1 and R2 are each independently selected from the group consisting of —H, —OH, —SH, C 1-4 straight or branched alkyl, C 1-4 straight or branched alkoxy, halogen, allyloxy, benzyloxy, aryloxy having one or more selected from the group consisting of hetero atoms and substituents, and heterocycloalkyl of 3 to 7 atoms having one or more hetero atoms, wherein the hetero atoms consist of 0, N and S; R3 is one selected from the group consisting of Ci-4 straight or branched alkyl, —NH 2 , —NHR4, —N(R4) 2 , and —OH; and R4 is C 1-4 straight or branched alkyl, wherein the compound defined by Formula 1 is selected from the group consisting of the following compounds; (1) (E)-4-(4-hydroxy-3-methoxyphenyl)-3-buten-2-one; (2) (E)-4-(3-hydroxy-4-methoxyphenyl)-3-buten-2-one; and (3) (E)-4-(3-fluoro-4-hydroxyphenyl)-3-buten-2-one. 2. A method for treating osteoporosis in a subject, the method comprising administering to the subject in need thereof an effective amount of a composition comprising a compound defined by Formula 1 below or the pharmaceutically acceptable salt thereof as an active ingredient: wherein, R1 and R2 are different from each other, R1 and R2 are each independently selected from the group consisting of —H, —OH, —SH, C 1-4 straight or branched alkyl, C 1-4 straight or branched alkoxy, halogen, allyloxy, benzyloxy, aryloxy having one or more selected from the group consisting of hetero atoms and substituents, and heterocycloalkyl of 3 to 7 atoms having one or more hetero atoms, wherein the hetero atoms consist of 0, N and S; R3 is one selected from the group consisting of Ci-4 straight or branched alkyl, —NH 2 , —NHR4, —N(R4) 2 , and —OH; and R4 is C 1-4 straight or branched alkyl, wherein the compound defined by Formula 1 is selected from the group consisting of the following compounds; (1) (E)-4-(3-hydroxy-4-methoxyphenyl)-3-buten-2-one; and (2) (E)-4-(3-fluoro-4-hydroxyphenyl)-3-buten-2-one.
Food compositions, function of food ingredients or processes for food or foodstuffs · CPC title
Geometrical isomers · CPC title
using additives (addition of substantially indigestible substances A23L33/21) · CPC title
substituted by doubly bound oxygen or sulphur atoms · CPC title
having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.